Purdue In The Lead To Bring Abuse-Deterrent Hydrocodone To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held specialty pharma released positive Phase III data on an abuse-deterrent extended-release hydrocodone formula, which, if approved, could put Zogenix’s Zohydro in jeopardy.